Press Release - Unaudited Financial Results for the quarter and half year ended September 30, 2026.

Evonile Pharma Limited (formerly known as Novartis India Limited) November 03, 2026 The Secretary, BSE Limited, Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001 Scrip Code: 500672 Subject: Press Release – Unaudited Financial Results for the quarter and half year ended September 30, 2026 Dear Sir/Madam, Further to our letter of today’s date on the outcome of the Board Meeting, and pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed the press release the Company proposes to issue on the unaudited financial results for the quarter and half year ended September 30, 2026. The press release will also be hosted on the website of the Company at www.evonilepharma.com Kindly take the same on record. Thank you, Yours faithfully, For Evonile Pharma Limited (formerly known as Novartis India Limited) Chandni Maru Company Secretary and Compliance Officer Membership No. ACS 60291 Registered Office: Inspire BKC, 7th Floor, Bandra-Kurla Complex, Bandra (East), Mumbai - 400051, Maharashtra, India. CIN: L24200MH1947PLC006104 | Tel: +91 22 50243000 Email: investor.relations@evonilepharma.com | Website: www.evonilepharma.com Evonile Pharma Limited (formerly known as Novartis India Limited) PRESS RELEASE Evonile Pharma (formerly Novartis India Limited) announces its first results after change of control  Builds an independent distribution and commercial platform; strengthens portfolio with acquisition of Minipress XL and entry into ophthalmology in India Mumbai, India; November 3, 2026: Evonile Pharma Limited (formerly known as Novartis India Limited) (BSE: 500672), a leading Domestic branded pharmaceuticals company with a legacy of nearly 80 years, today announced its unaudited financial results for the quarter and half year ended September 30, 2026. Q2 FY27 was a defining quarter in the Company’s history as ChrysCapital, one of India’s leading private equity investors, acquired a controlling 70.68% stake in the Company. The transaction brings one of India's longstanding pharmaceutical businesses under dedicated private equity ownership, with the ambition to build a leading branded-generics platform for the Indian market. Within two months of the change in control, Evonile Pharma has moved from a single-customer business model to marketing its brands with its own distribution network, field force and operating systems. At the same time, it has expanded into two attractive therapy areas, cardiology and ophthalmology, giving the business a broader and stronger base for the years ahead. Dr. Vikas Gupta, MD & CEO, Evonile Pharma Limited (formerly Novartis India Limited), said: “Following the transition from Novartis AG, Evonile Pharma has made significant progress in just a few months. Establishing our new business model requires an entirely new organisational foundation, and we have made considerable headway in putting the key building blocks in place. These efforts will position Evonile to emerge as one of India's progressive and forward-looking domestic pharmaceutical companies. During the quarter, we completed two strategic transactions: the acquisition of Minipress XL and an ophthalmology in-licensing agreement. Both are important steps in strengthening our portfolio, expanding our presence in key therapeutic areas and creating new platforms for sustainable growth. In H2 FY27, our priorities will be to complete the organisational build-out, establish an appropriate cost structure and bring together a strong team to lead Evonile's next phase of growth. While we are still at an early stage of this journey, the progress made so far gives us confidence. We are focused on building a robust organisation with the right capabilities, talent and ambition to unlock Evonile's full potential.” FINANCIAL PERFORMANCE Evonile Pharma recorded revenue from operations of ₹56.1 crore in Q2 FY27. Operating EBITDA (Earnings before Interest, Depreciation and Taxes) stood at -₹31.8 crore, reflecting one-time transition costs and upfront investment in the organisational build-out. For H1 FY27, revenue from operations stood at ₹159.9 crore and Profit after Tax at -₹45.3 crore. Results are not comparable with the previous year owing to the change in control and the change in business model. Registered Office: Inspire BKC, 7th Floor, Bandra-Kurla Complex, Bandra (East), Mumbai - 400051, Maharashtra, India. CIN: L24200MH1947PLC006104 | Tel: +91 22 50243000 Email: investor.relations@evonilepharma.com | Website: www.evonilepharma.com Evonile Pharma Limited (formerly known as Novartis India Limited) ABOUT EVONILE PHARMA Evonile Pharma Limited (formerly known as Novartis India Limited) (BSE: 500672) is a 100% India- focused branded pharmaceuticals company with a legacy of over 79 years. Its flagship brands, Voveran, Methergin, Calcium-Sandoz, Tegrital and Myfortic, hold #1 positions in their covered markets across pain management, gynaecology, wellness, neuroscience and transplant. Through the acquisition of Minipress XL and the in-licensing of a retina portfolio, the Company has added cardiology and ophthalmology. It runs an asset-light model and takes its portfolio to market through its own therapy-aligned field force and distribution network. ChrysCapital Group holds 70.68% of the Company. For more details on Evonile Pharma, please visit www.evonilepharma.com Investor Contact investor.relations@evonilepharma.com Registered Office: Inspire BKC, 7th Floor, Bandra-Kurla Complex, Bandra (East), Mumbai - 400051, Maharashtra, India. CIN: L24200MH1947PLC006104 | Tel: +91 22 50243000 Email: investor.relations@evonilepharma.com | Website: www.evonilepharma.com